Table 2 Comparison of variables between baseline, 12th and 24th weeks after administration of canagliflozin.
Baseline mean (SD) | 12-Week mean (SD) | p-value | 24-Week Mean (SD) | p-value | |
|---|---|---|---|---|---|
Weight (kg) | 74.05 ± 13.40 | 72.85 ± 13.70 | < 0.001 | 72.59 ± 13.80 | < 0.001 |
Body mass index (kg/m2) | 28.22 ± 4.30 | 27.75 ± 4.30 | < 0.001 | 27.56 ± 4.30 | < 0.001 |
Fat ratio (%) | 30.82 ± 11.50 | 30.72 ± 10.30 | 0.895 | 30.15 ± 11.00 | 0.781 |
HbA1c (%) | 7.50 ± 1.40 | 7.00 ± 0.80 | 0.01 | 7.00 ± 1.00 | 0.008 |
Fasting glucose (mg/dL) | 141.2 ± 45.3 | 126.8 ± 30.4 | 0.004 | 135.7 ± 57.9 | < 0.001 |
GOT | 31.2 ± 17.1 | 27.2 ± 16.6 | 0.087 | 27.1 ± 17.6 | 0.099 |
GPT | 34.5 ± 20.6 | 27.4 ± 12.8 | 0.008 | 28.4 ± 14.8 | 0.034 |
BUN (mg/dL) | 17.4 ± 5.5 | 19.4 ± 6.0 | 0.002 | 20.3 ± 7.2 | 0.014 |
Creatinine (mg/dL) | 1.0 ± 0.3 | 1.0 ± 0.3 | 0.292 | 1.0 ± 0.3 | 0.49 |
Estimated GFR (mL/min/1.73m2) | 68.7 ± 17.6 | 68.4 ± 21.4 | 0.844 | 67.7 ± 19.4 | 0.983 |
Sodium | 137.7 ± 2.4 | 138.1 ± 1.8 | 0.146 | 137.5 ± 1.9 | 0.642 |
Potassium | 4.3 ± 0.4 | 4.3 ± 0.5 | 0.747 | 4.4 ± 0.5 | 0.150 |
Uric acid | 5.9 ± 1.3 | 5.8 ± 1.6 | 0.723 | 6.1 ± 1.7 | 0.759 |
Triglyceride (mg/dL) | 145.7 ± 94.4 | 148.1 ± 115.5 | 0.869 | 160.3 ± 112.4 | 0.401 |
Microalb/Crea Ratio | 325.2 ± 786.7 | 238.6 ± 510.8 | 0.116 | 245.9 ± 751.8 | 0.176 |
LDL (mg/dL) | 78.7 ± 23.1 | 76.6 ± 22.9 | 0.584 | 74.3 ± 25.4 | 0.371 |
HDL (mg/dL) | 44.7 ± 13.3 | 43.6 ± 12.5 | 0.241 | 42.7 ± 10.6 | 0.295 |
Hematocrit (%) | 40.1 ± 3.6 | 41.5 ± 4.3 | < 0.001 | 42.5 ± 4.1 | < 0.001 |
NT-proBNP | 113.4 ± 121.6 | 131.5 ± 166 | 0.238 | 124.0 ± 134.4 | 0.688 |
Renin | 3.2 ± 5.2 | na | na | 5.8 ± 10.0 | 0.096 |
Aldosterone | 105.4 ± 89.7 | na | na | 111.5 ± 71.8 | 0.605 |
